title: Insulin-transferrin-selenium (ITS) improves maturation of porcine oocytes in vitro.
abstract: The objective of this study was to determine if insulin-transferrin-selenium (ITS) promoted a nuclear and cytoplasmic maturation of porcine oocytes that better supports subsequent embryonic development. The rate of oocyte in vitro maturation (IVM) in an experimental group treated with hormones for 42 h was significantly increased compared with that in a control group without hormone treatment (47.8% vs. 11.7%, respectively, p < 0.05). Following reduction of the hormone treatment period from 42 h to 21 h, which included both the first 21 h period of hormones treatment (45.4%) and the second 21 h period of hormone treatment (44.8%), the rate of oocyte IVM was still higher than that of the control group (p < 0.05). To improve porcine oocyte nuclear maturation, 1% ITS was added to medium supplemented with hormones. The rate of nuclear maturation in the ITS-treated group was significantly higher than in the ITS-untreated group (78.6% vs. 54.4%, respectively, p < 0.05). ITS treatment also significantly reduced the per cent of oocytes with type I and type III cortical granule (CG) distribution, respectively, and significantly increased the per cent of oocytes with type II CG distribution (85.3%). These observations indicated that the synchronization rates of nuclear and ooplasmic maturation reached 67.04% (78.56 × 85.33%). In conclusion, the combination of modified Tissue Culture Medium-199 (mM199) + 10 ng/ml epidermal growth factor (EGF) + 10 IU/ml pregnant mare serum gonadotrophin (PMSG) + 10 IU/ml human chorion gonadotrophin (hCG) + 2.5 IU/ml follicle stimulating hormone (FSH) + 1% ITS is suitable for culturing porcine oocytes in vitro, and effectively enhances porcine oocyte nuclear and cytoplasmic maturation.
authors.affiliation: College of Veterinary Medicine, Shaanxi Key Laboratory for Molecular Biology of Agriculture, Northwest A&F University, Yangling, Shaanxi 712100, China.
authors.forename: Junhe
authors.initials: J
authors.lastname: Hu
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Ma
authors.forename: Jian Chang
authors.initials: JC
authors.lastname: Bao
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: De
authors.initials: D
authors.lastname: Cheng
authors.forename: Zhimin
authors.initials: Z
authors.lastname: Gao
authors.forename: Anmin
authors.initials: A
authors.lastname: Lei
authors.forename: Chunrong
authors.initials: C
authors.lastname: Yang
authors.forename: Huayan
authors.initials: H
authors.lastname: Wang
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003593:Cytoplasm / Q000187:drug effects / Q000378:metabolism; D004622:Embryo, Mammalian / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D047108:Embryonic Development / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005260:Female; D006064:Gonadotropins, Equine / Q000494:pharmacology; D006736:Horses; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007124:Immunoenzyme Techniques; D007328:Insulin / Q000494:pharmacology*; D009865:Oocytes / Q000166:cytology* / Q000187:drug effects*; D009866:Oogenesis / Q000187:drug effects*; D011247:Pregnancy; D012643:Selenium / Q000494:pharmacology*; D013552:Swine; D014168:Transferrin / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; D007004:Hypoglycemic Agents; D007328:Insulin; D014168:Transferrin; D004815:Epidermal Growth Factor; D012643:Selenium